2268.HK

Contract drug services provider WuXi XDC Cayman Inc. (2268.HK) on Wednesday said its revenue grew by over 60% in the first half of 2025, while its adjusted net profit surged by more than 67%. The company added its net profit grew by more than 50% during the period, which would equal 740 million yuan or more based on its 490 million yuan ($68 million) profit in the year-ago period.

This strong growth owed largely to strong downstream demand from makers of antibody-drug conjugates (ADCs); the company’s leadership in the bioconjugate drug services market; and the rapid ramp-up of its newly commissioned production lines.

Shares of WuXi rose 8.6% to HK$53.65 on Wednesday. The stock is up 73% this year.

By Lau Chi Hang

To subscribe to Bamboo Works weekly free newsletter, clickhere

Recent Articles

Third-quarter revenue sets new record as Lens Technology approaches second “iPhone moment”

Lens Technology approaches second ‘iPhone moment’

The glass screen maker is betting big on AI glasses and embodied intelligence as its next major growth engines Key Takeaways: Lens Technology reported its revenue reached 207 billion yuan…